Dermatology

ModMed® Ranks #1 for Integrated Practice Management, Revenue Cycle Management and EHR in Surgical Specialties by Black Book Research for Sixth Consecutive Year

Retrieved on: 
Tuesday, April 16, 2024
Health Technology, Health Insurance, Data Management, Technology, Finance, Consulting, Surgery, Practice Management, Managed Care, Professional Services, Hospitals, Artificial Intelligence, Software, Data Analytics, Health, Electronic health record, Gastroenterology, Revenue cycle management, Ophthalmology, ENT, EHR, Urology, Dermatology, OBGYN, Senior, Pain management, Face, Practice management software, Multimedia, Allergy, Podiatry, Nursing

Specialty-specific healthcare technology leader ModMed® today announced its #1 ranking by Black Book™ Research for the sixth year in a row for Integrated Practice Management, Revenue Cycle Management and Electronic Health Record (EHR) in Surgical Specialties.

Key Points: 
  • Specialty-specific healthcare technology leader ModMed® today announced its #1 ranking by Black Book™ Research for the sixth year in a row for Integrated Practice Management, Revenue Cycle Management and Electronic Health Record (EHR) in Surgical Specialties.
  • "We are thrilled that ModMed has been recognized as the top provider of comprehensive solutions for the sixth year in a row.
  • Our solutions go beyond the traditional boundaries, fostering collaborative environments that enhance efficiency and performance," said Rob Ware, Senior Vice President of Revenue Cycle Management at ModMed.
  • Raman Mahabir, MD at Tucson Plastic Surgery, LLC, uses ModMed’s integrated Practice Management and EHR solutions at his practice.

Cutera® Announces the North America Launch of xeo®+

Retrieved on: 
Thursday, April 11, 2024
Biotechnology, Practice Management, Surgery, General Health, Health, Medical Devices, Hospitals, Health Technology, Doctor of Philosophy, ROI, IPL, Skin, Laser, Traction, History, Hair removal, Patient, XHO-FM, Physician, Multimedia, Aesthetics, Dermatology

Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announces the launch of xeo+, a pioneering laser and light-based multi-application platform built on a rich history of excellence in performance and innovation.

Key Points: 
  • Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announces the launch of xeo+, a pioneering laser and light-based multi-application platform built on a rich history of excellence in performance and innovation.
  • The xeo+ offers providers updated features and newly redesigned handpieces that allow for faster treatment times, optimized ease of use and an improved treatment experience.
  • “We developed an innovation inspired by the modern aesthetic practice building upon the over 20-year heritage of xeo.
  • The technology also includes a versatile range of newly redesigned laser and IPL handpieces, ranging from the CoolView®, Limelight®, Prowave, and Acutip™.

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Retrieved on: 
Thursday, April 11, 2024
Health, FDA, General Health, Research, Science, Pharmaceutical, Biotechnology, Efficacy, Safety, Gastroenterology, HES, Chronic obstructive pulmonary disease, Sinusitis, Social media, Polyp (medicine), Pharmacokinetics, Rheumatology, Conference call, Asthma, TATE, AstraZeneca, FY, Hypereosinophilic syndrome, Death, ClinicalTrials.gov, Dermatology, Conference, COPD, Webcast, Growth, Disease, Vasculitis, Respiratory Medicine, EGPA, Immunology, Metabolism, Diagnosis, Biomarker, PD, Biopharmaceutical, Ageing, Pharmaceutical industry

TATE was an open-label, Phase III trial evaluating the safety of FASENRA in children aged 6 to 11 years with severe eosinophilic asthma.

Key Points: 
  • TATE was an open-label, Phase III trial evaluating the safety of FASENRA in children aged 6 to 11 years with severe eosinophilic asthma.
  • The Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.
  • Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study).
  • Severe uncontrolled asthma in children: practical approach on diagnosis and management.

Thirty Madison's Nurx and Cove partner with Talkspace to expand mental health support for more than half a million women

Retrieved on: 
Thursday, April 25, 2024
Health, Anxiety, Migraine, Mental health, Partnership, Talkspace, Patient, Dermatology, Depression, Mental, Woman, Nursing

NEW YORK , April 25, 2024 /PRNewswire/ -- Thirty Madison, the specialty telemedicine company operating Keeps, Cove, and Nurx, today announced a partnership with Talkspace, a  leading online behavioral health company, to expand comprehensive mental health offerings for more than half a million women.

Key Points: 
  • NEW YORK , April 25, 2024 /PRNewswire/ -- Thirty Madison , the specialty telemedicine company operating Keeps, Cove, and Nurx, today announced a partnership with Talkspace , a  leading online behavioral health company, to expand comprehensive mental health offerings for more than half a million women.
  • Talkspace will serve as the recommended therapy partner for Thirty Madison brands Nurx , the leader in specialty, comprehensive care in women's health, and Cove , the largest virtual clinic treating migraine.
  • "Since we began offering Nurx patients mental health treatment in 2022, we have seen consistently strong and increasing demand.
  • By joining forces, Thirty Madison and Talkspace aim to address the growing demand with mental health experts and asynchronous care, readily available for patients whenever they need it.

Dr. Simon Ourian's Revolutionary Acne Scar Treatments Coolaser® and Neustem® at Epione Beverly Hills

Retrieved on: 
Wednesday, April 24, 2024
Multimedia, Epione, Patient, Dermatology, Beverly Hills, California, Acne, Skin, Medical device

BEVERLY HILLS, Calif., April 24, 2024 /PRNewswire-PRWeb/ -- Renowned cosmetic dermatology specialist Dr. Simon Ourian at Epione Beverly Hills introduces a groundbreaking solution to acne scars with two state-of-the-art technologies: Coolaser® and Neustem®. These cutting-edge treatments are transforming the approach to acne scar removal, providing patients with non-surgical options that deliver remarkable results with minimal downtime.

Key Points: 
  • At Epione Beverly Hills, Dr. Simon Ourian offers advanced dermatological treatments tailored for skin resurfacing with minimally invasive techniques.
  • BEVERLY HILLS, Calif., April 24, 2024 /PRNewswire-PRWeb/ -- Renowned cosmetic dermatology specialist Dr. Simon Ourian at Epione Beverly Hills introduces a groundbreaking solution to acne scars with two state-of-the-art technologies: Coolaser® and Neustem®.
  • These cutting-edge treatments are transforming the approach to acne scar removal, providing patients with non-surgical options that deliver remarkable results with minimal downtime.
  • For more information about Coolaser®, Neustem®, or to book a consultation with Dr. Simon Ourian, visit www.epionebh.com or contact Epione Beverly Hills directly at (310) 651-6267.

4 Tips for Flawless Summer-Ready Skin

Retrieved on: 
Wednesday, April 24, 2024
Collagen, Radiation, Sun protection, Humidity, Hyaluronic acid, Perspiration, Gland, Element, Cell, Pollution, Weather, Skin, UVB, Health, Thumb, Sunscreen, Skin cancer, Radical, Tanning, Pigment, Elastin, Attention, Dermatology, DNA, Pressure, HEV, Chemical substance, TLC, Antioxidant, Melanoma, Multimedia, Ageing, SPF, Swimming, Growth, UV, Cosmetics

A strong and healthy skin barrier helps retain moisture to keep your skin hydrated and repels harmful environmental pollutants.

Key Points: 
  • A strong and healthy skin barrier helps retain moisture to keep your skin hydrated and repels harmful environmental pollutants.
  • These products and protocols are specially designed to strengthen, restore, and protect the skin barrier, resulting in healthier and more resilient skin.
  • ZO® Exfoliating Polish sloughs off the dead skin cells and promotes new youthful skin.
  • These Med spa treatments help revive your complexion by shedding dead skin cells and unveiling fresher, brighter, and smoother skin underneath.

all® free clear Announces First-Ever Chief Dermatology Advisor

Retrieved on: 
Wednesday, April 24, 2024
Part, EPA, Skin, Dermatology, Cosmetics, Marketing, Acceptance, Pollen, Skin care, NEA, Pediatrics, Family, Patient, Allergy

STAMFORD, Conn., April 24, 2024 /PRNewswire/ -- all® free clear, the #1 detergent brand recommended by dermatologists for sensitive skin, today announced it is partnering with Dr. Lindsey Zubritsky – a board certified dermatologist and one of social media's most-followed "derm-fluencer" voices, encompassing more than two million followers across Instagram  and TikTok—as the brand's first-ever Chief Dermatology Advisor.

Key Points: 
  • Providing her expertise and serving as a liaison between all® free clear and consumers, the aim is to send a clear message: skin care can also happen in the laundry room.
  • Dr. Zubritsky will make her debut as Chief Dermatology Advisor for the all® free clear brand on the most-watched daytime talk show The View on May 8, 2024, at 11:00 a.m.
  • That's why I recommend a detergent brand like all® free clear for my patients and my own family.
  • all® free clear is the #1 detergent brand recommended for sensitive skin by dermatologists, allergists and pediatricians.

SciBase Partners with Al Shirawi Healthcare solutions to Offer Nevisense in UAE

Retrieved on: 
Wednesday, April 24, 2024
Health, Skin, Skin cancer, Elective surgery, Partnership, Patient, Dermatology

Through this partnership, Nevisense will now be available for patients in the United Arab Emirates (UAE).

Key Points: 
  • Through this partnership, Nevisense will now be available for patients in the United Arab Emirates (UAE).
  • Skin cancer is a growing problem in the UAE with official statistics suggesting that skin cancer accounts for about 14.5 per cent of cancer cases among males.
  • "We see the UAE as an attractive market with a passion for state-of-the-art, groundbreaking technologies.
  • General manager at Al Shirawi Healthcare solutions

Nibble Health Re-Launches As Standard Practice to Transform Medical Practice Operations

Retrieved on: 
Monday, April 22, 2024
AI, Cardiology, Software, Insurance, Human, Intelligence, GI, Patient, IVR, Physician, Dermatology, Pharmacy, Nursing

NEW YORK, April 22, 2024 /PRNewswire/ -- Standard Practice, a voice-AI platform for medical practices, today announced its official launch since pivoting from Nibble Health in December 2023. Co-founded by Steven Greene and Phil Markunas, Standard Practice automates medical practices' outbound calls to insurance and pharmacies. It offers medical providers a transformative solution that drives revenue while significantly alleviating their administrative burden.

Key Points: 
  • Co-founded by Steven Greene and Phil Markunas, Standard Practice automates medical practices' outbound calls to insurance and pharmacies.
  • However, in working with countless physicians, medical practice owners and their staff, they discovered a different gap in the market – the amount of time medical practices spend on the phone each day making outbound calls.
  • "Every medical office in the country should be using Standard Practice to automate their outbound calling to insurance.
  • By democratizing access to cutting-edge technology and world-class administrative workflows, Standard Practice empowers medical providers to go on the offensive and grow with maximum speed and efficiency.

OMNY Health launches new GI real-world data solutions in partnership with leading US gastroenterology practices

Retrieved on: 
Monday, April 22, 2024
Ulcerative colitis, Gastroenterology, Crohn's disease, Ophthalmology, Health, OMNY, Electronic health record, Partnership, Research, GI, Health information management, Patient, Ambulatory care, Short bowel syndrome, Data analysis, MBA, Internationalized domain name, Dermatology, Nursing

ATLANTA, April 22, 2024 /PRNewswire/ -- OMNY Health is pleased to announce its partnership with the nation's leading community-based independent gastroenterology (GI) practices and integrated delivery networks (IDNs) to launch a novel set of real-world data and evidence solutions for research. Over 5,000 GI providers serving more than 10 million patients are now part of OMNY's research network, representing care delivery by over 380,000 providers and 75 million patients across the US. The focus on GI practice data is a notable expansion to OMNY's real-world data ecosystem, which works with providers to support compliant research partnerships at scale. OMNY works with health systems to enable insights on patient population characteristics, care delivery patterns, and treatment outcomes based on data extracted from de-identified inpatient and ambulatory care electronic health records (EHRs). OMNY's solutions deliver valuable information on disease severity, rationale behind treatment decisions, treatment efficacy, and impact of social determinants on treatment selection and disease progression. By integrating disparate EHRs into unified, de-identified research data products, OMNY offers researchers and providers the breadth and depth of information needed to address their biomedical and population health research questions.

Key Points: 
  • ATLANTA, April 22, 2024 /PRNewswire/ -- OMNY Health is pleased to announce its partnership with the nation's leading community-based independent gastroenterology (GI) practices and integrated delivery networks (IDNs) to launch a novel set of real-world data and evidence solutions for research.
  • "We are thrilled to announce our partnership with OMNY Health, which allows us to drive further insights from our data to advance patient care."
  • Our partnership with OMNY helps ensure our providers have the data and support they need to deliver easy-to-access exceptional GI care."
  • We look forward to building on that impact in the field of gastroenterology," said Mitesh Rao, MD, CEO, OMNY Health.